HRP980484A2 - Novel carboxylic acid derivatives, their production and their their use as mixed eta/etb receptor antagonists - Google Patents
Novel carboxylic acid derivatives, their production and their their use as mixed eta/etb receptor antagonistsInfo
- Publication number
- HRP980484A2 HRP980484A2 HR19811915.1A HRP980484A HRP980484A2 HR P980484 A2 HRP980484 A2 HR P980484A2 HR P980484 A HRP980484 A HR P980484A HR P980484 A2 HRP980484 A2 HR P980484A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- substituted
- alkoxy
- haloalkyl
- phenyl
- Prior art date
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- -1 alkali metal cation Chemical class 0.000 claims description 82
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 23
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 150000003254 radicals Chemical class 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 239000011593 sulfur Chemical group 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 11
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 10
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 10
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 5
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- FONOSWYYBCBQGN-UHFFFAOYSA-N ethylene dione Chemical group O=C=C=O FONOSWYYBCBQGN-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 150000005840 aryl radicals Chemical class 0.000 claims description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 102000002045 Endothelin Human genes 0.000 description 10
- 108050009340 Endothelin Proteins 0.000 description 10
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000002585 base Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 102100040611 Endothelin receptor type B Human genes 0.000 description 5
- 102100033902 Endothelin-1 Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 150000001735 carboxylic acids Chemical class 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 101800004490 Endothelin-1 Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MJXSDNAEQWGZGP-UHFFFAOYSA-N 2-hydroxy-3-methoxy-3,6-diphenylhexanoic acid Chemical compound C=1C=CC=CC=1C(OC)(C(O)C(O)=O)CCCC1=CC=CC=C1 MJXSDNAEQWGZGP-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000005466 alkylenyl group Chemical group 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- HZZGDPLAJHVHSP-GKHTVLBPSA-N big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002308 endothelin receptor antagonist Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QABLOFMHHSOFRJ-UHFFFAOYSA-N methyl 2-chloroacetate Chemical compound COC(=O)CCl QABLOFMHHSOFRJ-UHFFFAOYSA-N 0.000 description 2
- MTDIXZBROJJEMX-UHFFFAOYSA-N methyl 3-phenyl-3-(3-phenylpropyl)oxirane-2-carboxylate Chemical compound COC(=O)C1OC1(C=1C=CC=CC=1)CCCC1=CC=CC=C1 MTDIXZBROJJEMX-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- 125000004711 1,1-dimethylethylthio group Chemical group CC(C)(S*)C 0.000 description 1
- GBUMEGLMTNAXOM-UHFFFAOYSA-N 1,4-diphenylbutan-1-one Chemical compound C=1C=CC=CC=1C(=O)CCCC1=CC=CC=C1 GBUMEGLMTNAXOM-UHFFFAOYSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004781 2,2-dichloro-2-fluoroethyl group Chemical group [H]C([H])(*)C(F)(Cl)Cl 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- KPTPREQPJGCQBH-UHFFFAOYSA-N 2-(4,6-dimethylpyrimidin-2-yl)oxy-3,6-diphenyl-3-[2-(3,4,5-trimethoxyphenyl)ethoxy]hexanoic acid Chemical compound COc1cc(CCOC(CCCc2ccccc2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)cc(OC)c1OC KPTPREQPJGCQBH-UHFFFAOYSA-N 0.000 description 1
- AMTCWKOTBYLRBD-UHFFFAOYSA-N 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,6-diphenylhexanoic acid Chemical compound N=1C(C)=CC(C)=NC=1OC(C(O)=O)C(C=1C=CC=CC=1)(OC)CCCC1=CC=CC=C1 AMTCWKOTBYLRBD-UHFFFAOYSA-N 0.000 description 1
- DZJCKEJIFNQWSP-UHFFFAOYSA-N 2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenyl-3-[2-(3,4,5-trimethoxyphenyl)ethoxy]hexanoic acid Chemical compound COC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OCCC=2C=C(OC)C(OC)=C(OC)C=2)C=2C=CC=CC=2)=N1 DZJCKEJIFNQWSP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- OWERJMBAZKUAGS-UHFFFAOYSA-N 3-[(3,4-dimethoxyphenyl)methoxy]-2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenylhexanoic acid Chemical compound COc1cc(C)nc(OC(C(O)=O)C(CCCc2ccccc2)(OCc2ccc(OC)c(OC)c2)c2ccccc2)n1 OWERJMBAZKUAGS-UHFFFAOYSA-N 0.000 description 1
- GKGRDCADRYKKPO-UHFFFAOYSA-N 3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenylhexanoic acid Chemical compound COC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OCCC=2C=C(OC)C(OC)=CC=2)C=2C=CC=CC=2)=N1 GKGRDCADRYKKPO-UHFFFAOYSA-N 0.000 description 1
- MVZSVIWKRHKBFP-UHFFFAOYSA-N 3-[2-(4-hydroxy-3-methoxyphenyl)ethoxy]-2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenylhexanoic acid Chemical compound COC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OCCC=2C=C(OC)C(O)=CC=2)C=2C=CC=CC=2)=N1 MVZSVIWKRHKBFP-UHFFFAOYSA-N 0.000 description 1
- QSNKQHXTPVICBY-UHFFFAOYSA-N 3-methoxy-2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenylhexanoic acid Chemical compound COC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OC)C=2C=CC=CC=2)=N1 QSNKQHXTPVICBY-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- LHXVWEHJQRXCIW-UHFFFAOYSA-N 4-[[1-carboxy-1-(4,6-dimethylpyrimidin-2-yl)oxy-2,5-diphenylpentan-2-yl]oxymethyl]benzoic acid Chemical compound CC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OCC=2C=CC(=CC=2)C(O)=O)C=2C=CC=CC=2)=N1 LHXVWEHJQRXCIW-UHFFFAOYSA-N 0.000 description 1
- QNCXYVGMOBWGQT-UHFFFAOYSA-N 4-[[1-carboxy-1-(4-methoxy-6-methylpyrimidin-2-yl)oxy-2,5-diphenylpentan-2-yl]oxymethyl]benzoic acid Chemical compound COC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC=CC=C1)(C1=CC=CC=C1)OCC1=CC=C(C=C1)C(=O)O QNCXYVGMOBWGQT-UHFFFAOYSA-N 0.000 description 1
- GNAQBURBJPHPGP-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-(4-methoxyphenoxy)-3-phenylhexanoic acid Chemical compound COc1ccc(OC(CCCc2ccc(OC)c(OC)c2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)cc1 GNAQBURBJPHPGP-UHFFFAOYSA-N 0.000 description 1
- FQNJICCGMPBQRN-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-3-[(3,4-dimethoxyphenyl)methoxy]-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-phenylhexanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCCC(C=1C=CC=CC=1)(C(OC=1N=C(C)C=C(C)N=1)C(O)=O)OCC1=CC=C(OC)C(OC)=C1 FQNJICCGMPBQRN-UHFFFAOYSA-N 0.000 description 1
- SENQOFMCFSPGJF-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-hydroxy-3-phenylhexanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCCC(C=1C=CC=CC=1)(C(O)C(O)=O)OCCC1=CC=C(OC)C(OC)=C1 SENQOFMCFSPGJF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- YKFRGYORNHGJOL-FYJGNVAPSA-N CC1=CC(=NC(=N1)OC(C(=O)O)C(CCCC2=CC=CC=C2)(C3=CC=CC=C3)O/C=C/CC4=CC(=C(C(=C4)OC)OC)OC)C Chemical compound CC1=CC(=NC(=N1)OC(C(=O)O)C(CCCC2=CC=CC=C2)(C3=CC=CC=C3)O/C=C/CC4=CC(=C(C(=C4)OC)OC)OC)C YKFRGYORNHGJOL-FYJGNVAPSA-N 0.000 description 1
- UTXWEWXWUSYBBB-UHFFFAOYSA-N CC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC(=C(C=C1)OC)OC)(C1=CC=CC=C1)OC Chemical compound CC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC(=C(C=C1)OC)OC)(C1=CC=CC=C1)OC UTXWEWXWUSYBBB-UHFFFAOYSA-N 0.000 description 1
- SVSOIQVXTQCIRX-UHFFFAOYSA-N COC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC=CC=C1)(C1=CC=CC=C1)OC1=CC=C(C=C1)OC Chemical compound COC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC=CC=C1)(C1=CC=CC=C1)OC1=CC=C(C=C1)OC SVSOIQVXTQCIRX-UHFFFAOYSA-N 0.000 description 1
- QQOJAUDHRJYJLM-UHFFFAOYSA-N COc1cc(CCOC(CCCc2ccccc2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)ccc1O Chemical compound COc1cc(CCOC(CCCc2ccccc2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)ccc1O QQOJAUDHRJYJLM-UHFFFAOYSA-N 0.000 description 1
- ZFWZTWNUSDFTFL-UHFFFAOYSA-N COc1ccc(CCOC(CCCc2ccccc2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)cc1OC Chemical compound COc1ccc(CCOC(CCCc2ccccc2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)cc1OC ZFWZTWNUSDFTFL-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical compound CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 101100017604 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HOR7 gene Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WJWOJXJNPRGALQ-AATRIKPKSA-N n1c(C)cc(C)nc1OC(C(O)=O)C(CCCc1ccccc1)(OCC/C=C/CC)c1ccccc1 Chemical compound n1c(C)cc(C)nc1OC(C(O)=O)C(CCCc1ccccc1)(OCC/C=C/CC)c1ccccc1 WJWOJXJNPRGALQ-AATRIKPKSA-N 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- CMMXCVYESRODNH-UHFFFAOYSA-N trichloroepoxyethane Chemical class ClC1OC1(Cl)Cl CMMXCVYESRODNH-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Predloženi izum odnosi se na nove derivate karboksilnih kiselina i njihovo pripravljanje i upotrebu.
Endotelin je peptid izgrađen od 21 amino kiseline, kojeg sintetizira i oslobađa vaskularni endotel. Endotelin postoji u tri izomerna oblika, ET-1, ET-2 i ET-3. Kako se ovdje rabi, pojam “endotelin” ili “ET” odnosi se na jedan ili na sve izomerne oblike endotelina. Endotelin je jaki vazokonstriktor i snažno djeluje na tonus krvnih žila. Poznato je, da tu vazokonstrikciju uzrokuje vezanje endotelina na njegov receptor (Nature, 332, (1988) 411-415; FEBS Letters, 231, (1988) 440-444 i Biochem. Biophys. Res. Commun., 154, (1988) 868-875.
Povišeno ili nenormalno oslobađanje endotelina uzrokuje trajnu kontrakciju žila u perifernim, renalnim i cerebralnim krvnim žilama, koja može dovesti do zdravstvenih poremećaja. Iz literature je poznato da je endotelin uključen u brojne zdravstvene poremećaje. To su hipertenzija, akutni miokardijalni infarkt, plućna hipertenzija, Raynaudov sindrom, cerebralne vazospazme, udar, benigna hipertrofija prostate, ateroskleroza i astma (J. Vascular Med. Biology 2, (1990) 207, J. Am. Med. Association 264, (1990) 2868, Nature 344, (1990) 114, N. Engl. J. Med. 322, (1989) 205, N. Engl. J. Med. Chem. 328, (1993) 1732, Nephron 66, (1994) 373, Stroke 25, (1994) 904, Nature 365, (1993), 759, J. Mol. Cell. Cardiol. 27, (1995) A234; Cancer Research 56, (1996) 663).
Zasada su u literaturi opisana najmanje dva podtipa endotelin-receptora, ETA i ETB receptori (Nature 348, (1990) 730, Nature 348, (1990) 732). Prema tome, tvari koje inhibiraju vezanje endotelina na dva receptora, trebale bi antagonizirati fiziološke efekte endotelina i stoga predstavljaju dragocjene lijekove.
WO 96/11914 opisuje derivate karboksilne kiseline koji se, međutim, vežu s visokim afinitetom na ETA receptor i sa značajno nižim afinitetom na ETB receptor (koji su nazvani ETA-specifični receptori).
Mi ovdje smatramo antagoniste ETA-specifičnim ako je njihov afinitet za ETA receptor barem deset puta viši od njegovog afiniteta za ETB receptor.
Cilj predloženog izuma je osigurati endotelin receptor antagoniste koji se vežu na ETA i na ETB receptore (koji su nazvani miješani antagonisti).
Grubo uzevši, jednaki afinitet za receptore znači da je omjer afiniteta veći od 0,1 i manji od 10.
Izum se odnosi na derivate karboksilne kiseline formule I
[image]
u kojoj supstituenti imaju slijedeća značenja:
R predstavlja tetrazol (sic) ili skupinu
[image]
R1 je radikal OR7 gdje
R7 predstavlja vodik, kation alkalijskog metala, kation zemno alkalijskog metala ili fiziološki podnošljiv organski amonijev ion;
C3-C8-cikloalkil, C1-C8-alkil,
CH2-fenil, supstituiran ili nesupstituiran,
C3-C8-alkenilnu ili C3-C8-alkinilnu skupinu, nesupstituiranu ili supstituiranu, ili
fenil, supstituiran ili nesupstituiran,
R2 je vodik, hidroksil, NH2, NH (C1-C4-alkil), N (C1-C4-alkil)2, halogen, C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi ili C1-C4-alkiltio, ili je CR2 vezan na CR10, kako je dolje navedeno, čime se dobije petero- ili šesteročlani prsten, ili ako Het predstavlja peteročlani prsten, CR2 također može biti zajedno sa CR3 petero- ili šesteročlani alkenilni ili alkinilni prsten koji nije supstituiran ili je supstituiran;
X je dušik ili metin;
Y je dušik ili metin;
W je dušik ili CR10, gdje R10 predstavlja vodik ili C1-C4-alkil, ili CR10 zajedno sa CR2 ili CR3 oblikuje petero- ili šesteročlani alkilenski ili alkenilni prsten, koji nije supstituiran ili je supstituiran, i u kojem u svakom slučaju jedna ili više metilenskih skupina može biti nadomješteno s kisikom, sumporom, -NH ili NH (C1-C4-alkilom);
R3 je vodik, hidroksil, NH2, NH (C1-C4-alkil), N (C1-C4-alkil)2, halogen, C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, C1-C4-alkiltio; ili je CR3 povezan na CR10 kako je gore navedeno čime se dobije petero- ili šesteročlani prsten;
R4 i R3 (koji mogu biti jednaki ili različiti) jesu:
fenil ili naftil, nesupstituiran ili supstituiran, ili
fenil ili naftil koji su izravnom vezom zajedno povezani u orto položajima, metilenska, etilenska, ili etenilenska skupina, kisikov ili sumporni atom ili SO2, NH ili N-alkilna skupina,
C3-C8-cikloalkil, nesupstituiran ili supstituiran;
R6 je vodik, C1-C8-alkil, C3-C8-alkenil ili C3-C8-alkinil, pri čemu svaki od tih radikala može biti jednostruko ili višestruko supstituiran s halogenim, hidroksilom, merkapto, karboksilom, nitro, amino, cijano, C1-C4-alkoksi, C3-C6-alkeniloksi, C3-C6-alkiniloksi, C1-C4-alkiltio, C1-C4-haloalkoksi, C1-C4-alkilkarbonil, C1-C4-alkoksikarbonilom, C3-C8-alkilkarbonilalkilom, NH (C1-C4-alkilom), N (C1-C4-alkilom)2, C3-C8-cikloalkilom, hetariloksi ili hetarilom, petero- ili šesteročlanim, koji sadrži jedan od tri dušikova atoma i/ili sumporni ili kisikov atom, fenoksi ili fenilom, pri čemu spomenuti arilni radikali sa svoje strane mogu biti jednostruko ili višestruko, npr. jednostruko do trostruko, supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano,C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1 -C4-haloalkoksi, amino, NH (C1-C4-alkilom), ili C1-C4-alkiltio;
fenil ili naftil, od kojih svaki može biti jednostruko ili višestruko supstituiran sa slijedećim radikalima: halogen, nitro, cijano, hidroksil, amino, C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, fenoksi, C1-C4-alkiltio, C1-C4-alkilamino, C1-C4-dialkilamino, dioksometilen ili dioksoetilen;
petero- šesteročlani heteroaromatski sistem koji sadrži jedan do tri dušikova atoma i/ili jedan atom sumpora ili kisika, koji može nositi jedan do četiri halogena atoma i/ili jedan do dva slijedeća radikala: C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, C1-C4-alkiltio, fenil, fenoksi ili fenilkarbonil, pri čemu fenilni radikali sa svoje strane nose jedan do pet halogenih atoma i/ili jedan do tri slijedeća radikala: C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, i/ili C1-C4alklitio;
C3-C8-cikloalkil, pri čemu ti radikali mogu biti jednostruko ili višestruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano, C1-C4-alkilom, C2-C4-alkenilom, C2-C4-alkinilom, C1-C4-alkoksi, C1-C4-alkiltio, C1-C4-haloalkoksi;
Z je sumpor ili kisik;
B je C2-C4-alkilen;
Het je heterociklički radikal formule Ia ili Ib
[image]
gdje
T je O, S ili NR8;
R8 je C1-C6-alkil,
i njihove fiziološke podnošljive soli i enantiomerni čisti oblici.
U toj svezi i u nastavku primjenjuju se slijedeće definicije:
Alkalijski metal je npr. litij, natrij, kalij;
Zemno alkalijski metal je npr. kalcij, magnezij, barij;
C3-C8-cikloalkil je npr. ciklopropil, ciklobutil, ciklopentil, cikloheksil, cikloheptil ili ciklooktil;
C1-C4-haloalkil može biti linearan ili razgranat, kao npr. fluormetil, difluormetil, trifluormetil, klordifluormetil, diklorfluormetil, triklormetil, 1-fluoretil, 2-fluoretil, 2,2-difluoretil, 2,2,2-trifluoretil, 2-klor-2,2-difluoretil, 2,2-diklor-2-fluoretil, 2,2,2-trikloretil ili pentafluoretil;
C1-C4-haloalkoksi može biti linearan ili razgranat, kao npr. difluormetoksi, trifluormetoksi, klordifluormetoksi, 1-fluoretoksi, 2,2-difluoretoksi, 1,1,2,2-difluoretoksi, 1,1,2,2-tetrafluoretoksi, 2,2,2-trifluoretoksi, 2-klor-1,1,2-trifluoretoksi, 2-fluoretoksi ili pentafluoretoksi;
C1-C4-alkil može biti linearan ili razgranat, kao npr. metil, etil, 1-propil, 2-propil, 2-metil-2-propil, 2-metil-1-propil, 1-butil ili 2-butil;
C2-C4-alkenil može biti linearan ili razgranat, kao npr. etenil, 1-propen-3-il, 1-propen-2-il, 1-propen-1-il, 2-metil-1-propenil, 1-butenil ili 2-butenil;
C2-C4-alkinil može biti linearan ili razgranat, kao npr. etenil, 1-propin-1-il, 1-propin-3-il, 1-butin-4-il ili 2-butin-4-il;
C1-C4-alkoksi može biti linearan ili razgranat, kao npr. metoksi, etoksi, propoksi, 1-metiletoksi, butoksi, 1-metilpropoksi, 2-metilpropoksi ili 1,1-dimetiletoksi;
C3-C6-alkeniloksi može biti linearan ili razgranat, kao npr. alkiloksi, 2-buten-1-iloksi ili 3-buten-2-iloksi;
C3-C6-alkiniloksi može biti linearan ili razgranat, kao npr. 2-propin-1-iloksi, 2-butin-1-iloksi ili 3-butin-2-iloksi;
C1-C4-alkiltio može biti linearan ili razgranat, kao npr. metiltio, etiltio, propiltio, 1-metiletiltio, butiltio, 1-metilpropiltio, 2-metilpropiltio ili 1,1-dimetiletiltio;
C1-C4-alkilkarbonil može biti linearan ili razgranat, kao npr. acetil, etilkarbonil, ili 2-propilkarbonil;
C1-C4-alkoksikarbonil može biti linearan ili razgranat, kao npr. metoksikarbonil, etoksikarbonil, n-propoksikarbonil, i-propoksikarbonil ili n-butoksikarbonil;
C3-C8-alkilkarbonilalkil može biti linearan ili razgranat, kao npr. 2-okso-prop-1-il, 3-okso-but-1-il ili 3-okso-but-2-il;
C1-C8-alkil može biti linearan ili razgranat, kao npr. pentil, heksil, heptil ili oktil;
halogen je npr. fluor, klor, brom, jod.
Izum se nadalje odnosi na spojeve iz kojih se mogu osloboditi spojevi formule I (tzv. pred-lijekovi).
Prednosni pred-lijekovi su oni kod kojih se oslobađanje odvija pod uvjetima koji su slični uvjetima koji vladaju u određenim dijelovima tijela, npr. u želucu, crijevima, krvotoku, jetri.
Spojevi i intermedijati za njihovu proizvodnju, kao npr. II, III i IV mogu imati jedan ili više asimetrično supstituiranih ugljikovih atoma. Takvi spojevi mogu postojati kao čisti enantiomeri diastereomeri ili kao njihove smjese. Pri upotrebi kao aktivne tvari, prednost se daje upotrebi enantiomerno čistog spoja.
Izum se nadalje odnosi na upotrebu gore navedenih derivata karboksilne kiseline za proizvodnju lijekova, posebno za proizvodnju inhibitora ETA i ETB receptora. Spojevi prema izumu posebno su prikladni kao miješani antagonisti, kako su definirani uvodno.
Spojevi opće formule IV, u kojoj Z predstavlja sumpor ili kisik, mogu se proizvesti - također u enatiomerno čistom obliku - kako je opisano u WO 96/11914.
[image]
Spojevi opće formule III su poznati ili se mogu sintetizirati npr. redukcijom odgovarajućih karboksilnih kiselina ili njihovih estera, ili također nekom drugom opće poznatom metodom.
Spojevi prema izumu u kojima supstituenti imaju značenja utvrđena za formulu I mogu se proizvesti, na primjer, reakcijom derivata karboksilne kiseline formule IV, u kojoj supstituenti imaju navedeno značenje, sa spojevima formule V.
[image]
R11 u formuli V je halogen ili R12 -SO2, gdje R12 može biti C1-C4-alkil, C1-C4-haloalkil ili fenil. K tome, barem jedan od članova prstena X ili Y je dušik. Reakcija se odvija ponajprije u inertnom otapalu ili u sredstvu za razređivanje, uz dodatak prikladne baze, tj. baze koja deprotonira intermedijat IV, pri temperaturi u rasponu od sobne temperature do vrelišta otapala.
Spojevi tipa I sa R = COOH mogu se dobiti nadalje izravno ako se međusproizvod IV, u kojem R predstavlja COOH, deprotonira s dva ekvivalenta odgovarajuće baze i reagira sa spojevima opće formule V. Ta se reakcija također odvija u inertnom otapalu i pri temperaturi u području od sobne temperature do vrelišta otapala.
Primjeri takovih otapala, odnosno sredstava za razređenje jesu alifatski, aliciklički i aromatski ugljikovodici, koji po potrebi mogu biti klorirani, kao npr. heksan, cikloheksan, petroleter, nafta, benzen, ksilen, metilen klorid, kloroform, tetraklorugljik, etil klorid i trikloretilen, eteri, kao na primjer diizopropil eter, dibutil eter, metil terc. butil eter, propilen oksid, dioksan i tetrahidrofuran, nitrili kao na primjer acetonitril i propionitril, amidi kao dimetilformamid, dimetilacetamid i N-metilpirolidon, sulfoksidi i sulfoni, kao na primjer dimetil sulfoksid i sulfolan.
Spojevi formule V su poznati, u nekim slučajevima se mogu kupiti ili se mogu proizvesti po opće poznatim metodama.
Kao baza može poslužiti hidrid alkalijskog ili zemno alkalijskog metala, ako natrijev hidrid, kalijev hidrid ili kalcijev hidrid, karbonat kao alkalijski karbonat, npr. natrijev ili kalijev karbonat, hidroksid alkalijskog ili zemno alkalijskog, metala kao natrijev ili kalijev hidroksid, organometalni spoj kao butil-litij ili amid alkalijskog metala, kao litijev diizopropilamid ili litijev amid.
Spojevi formule I mogu se proizvesti također i tako da se pođe od odgovarajućih karboksilnih kiselina, tj. spojeva formule I u kojima R1 predstavlja COOH i oni se najprije na uobičajen način prevedu u aktivirani oblik, kao što je kiselinski halogenid, anhidrid ili imidazol, a ti se zatim kemijski pretvaraju s odgovarajućim hidroksilnim spojem HOR7. Ta pretvorba se može provesti u uobičajenim otapalima i često je potreban dodatak baze, pri čemu u obzir dolaze gore navedene. Obadva stupnja mogu se također pojednostavniti time da se karboksilnu kiselinu pusti djelovati na hidroksilni spoj u prisutnosti sredstva za dehidrataciju, kao što je karbodiimid.
Osim toga, spojevi formule I mogu se također proizvesti i tako da se pođe od soli odgovarajućih karboksilnih kiselina, tj. spojeva formule I u kojima R1 predstavlja skupinu COR, a R je OM, pri čemu M može biti kation alkalijskog metala ili ekvivalent kationa zemno alkalijskog metala. Te soli mogu se dovesti u reakciju s mnogim spojevima formule R-A, pri čemu A predstavlja uobičajenu nukleofilnu otpusnu skupinu, primjerice halogen, kao klor, brom, jod, ili s haloalkilom nasupstituirani ili s halogenim, alkilom ili s haloalkilom supstituirani aril ili alkilsulfonil, kao npr. toluensulfonil i metilsulfonil ili neku drugu ekvivalentnu polaznu skupinu. Spojevi formule R-A s reaktivnim supstituentom A, su poznati ili se lako mogu dobiti na osnovi općeg stručnog znanja. Ta se reakcija može provesti u uobičajenim otapalima i vrši se ponajprije uz dodatak baze,a u tom slučaju su prikladne gore navedene.
Što se tiče biološkog djelovanja, prednost se daje derivatima karboksilnih kiselina opće formule I - također kao čistim enantiomerima, odnosno čistim diastereomerima ili kao njihovim smjesama, u kojima supstituenti imaju slijedeća značenja:
R1 je COOR7 gdje R7 je:
vodik, kation alkalijskog metala, kation zemno alkalijskog metala ili fiziološki podnošljiv amonijev ion;
C3-C8-cikloalkil, C1-C8-alkil,
CH2-fenil, nesupstituiran ili supstituiran,
C3-C6-alkenilna ili C3-C6-alkinilna skupina, nesupstituirana ili supstituirana, ili
fenil, nesupstituiran ili supstituiran,
R2 je vodik, hidroksil, halogen, N (C1-C4)2, C1-C4-alkil, C1-C4-alkoksi, C1-C4-haloalkil, C1-C4-haloalkoksi, ili je CR2 vezan na CR10 kako je dolje navedeno čime se dobije petero- ili šesteročlani prsten, ili ako Het predstavlja peteročlani prsten, CR2 također može biti zajedno sa CR3 petero- ili šesteročlani alkenilni ili alkilenilni prsten koji nije supstituiran ili je supstituiran;
X je dušik ili metin;
Y je dušik ili metin;
W je dušik ili CR10; gdje CR10 predstavlja vodik ili C1-C4-alkil, ili CR10 zajedno sa CR2 ili CR3 oblikuje petero- ili šesteročlani alkilenski ili alkenilenski prsten koji može biti supstituiran s jednom ili dvije metilne skupine gdje u svakom slučaju metilenska skupina može biti nadomještena s kisikom ili sumporom, kao što je kao -CH2-CH2-O-, -CH2-CH2-CH2-O-, -CH=CH-O-, -CH=CH-CH2-O-, -CH(CH3)-CH(CH3)-O-, -CH=C(CH3)-O-, -C(CH3)=C(CH3)-O-, ili C(CH3)=C(CH3)-S;
najmanje jedan od članova prstena, X, Y ili W, je dušik;
R3 je vodik, hidroksil, halogen, N (C1-C4-alkil)2, C1-C4-alkil, C1-C4-alkoksi, C1-C4-alkiltio, C1-C4-haloalkil, C1-C4-haloalkoksi ili je CR3 povezan na CR10, kako je gore navedeno, čime se dobije petero- ili šesteročlani prsten; ili ako Het predstavlja peteročlani prsten, CR2 također može sa CR3 biti petero- ili šesteročlani alkenilni ili alkilenilni prsten koji nije supstituiran ili je supstituiran;
R4 i R5 (koji mogu biti jednaki ili različiti) predstavljaju:
fenil ili naftil, koji može biti supstituiran s jednim ili više slijedećih ostataka: halogen, nitro, cijano, hidroksil, merkapto, amino, C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, fenoksi, C1-C4-alkiltio, NH (C1-C4-alkil) ili N (C1-C4-alkil)2 ili fenil, koji može biti jednostruko ili višestruko supstituiran, npr. jednostruko do trostruko, s halogenim, nitro, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi, ili sa C1-C4-alkiltio; ili
fenil ili naftil, koji su u orto položaju međusobno povezani preko izravne veze, metilenske, etilenske ili etenilne skupine, kisikovog ili sumpornog atoma ili jedne SO2-, NH- ili N-alkilne skupine;
C3-C8-cikloalkil;
R6 predstavlja C3-C8-cikloalkil, pri čemu ti ostaci mogu biti jednostruko ili višestruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano, C1-C4-alkoksi, C1-C4-alkilom, C2-C4-alkenilom, C2-C4-alkinilom, C3-C6-alkeniloksi, C3-C6-alkiniloksi, C1-C4-alkiltio, C1-C4-haloalkoksi, C1-C4-alkilkarbonilom, C1-C4-alkoksikarbonilom, NH (C1-C4-alkilom), N (C1-C4-alkilom)2 ili fenilom, koji može biti jednostruko ili višestruko supstituiran, npr. jednostruko do trostruko, s halogenim, nitro, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi ili C1-C4-alkiltio;
fenil ili naftil, koji može biti supstituiran s jednim ili više slijedećih ostataka: halogen, nitro, merkapto, karboksil, cijano, hidroksil, amino, C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, C3-C6-alkeniloksi, C1-C4-haloalkil, C3-C6-akiniloksi, C1-C4-alkilkarbonil, C1-C4-alkoksikarbonil, C1-C4-alkoksi, C1-C4-haloalkoksi, fenoksi, C1-C4-alkiltio, NH (C1-C4-alkil), N (C1-C4-alkil)2, dioksometilen, dioksoetilen (sic) ili fenil, koji može biti jednostruko ili višestruko, npr. jednostruko do trostruko, supstituiran s halogenim nitro, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi ili C1-C4-alkiltio;
petero- ili šesteročlani heteroaromat, koji sadrži jedan do tri dušikova atoma i/ili sumporni ili kisikov atom, koji može nositi jedan do četiri halogena atoma i/ili jedan do dva slijedeća radikala: C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, C1-C4-alkiltio, fenil, fenoksi ili fenilkarbonil, pri čemu fenilni ostaci sa svoje strane mogu nositi jedan do pet halogenih atoma i/ili jedan do tri slijedeća radikala: C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi i/ili C1-C4-alkiltio;
Z je sumpor ili kisik;
B je C2-C4-alkilen;
Het je heterociklička skupina formule Ia ili Ib sa T= 0, S.
Posebno prednosni spojevi formule I, obje vrste, naime kao čisti enantiomeri i kao čisti diastereomeri i kao njihova smjesa, jesu oni u kojima supstituenti imaju slijedeća značenja:
Rʹ je COOH;
X, Y je N;
W je CR10;
R2 i R3 predstavljaju vodik, hidroksil, NH2, NH (C1-C4-alkil), N (C1-C4)2, halogen, C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi ili C1-C4-alkiltio, ili je CR2 povezan na CR10, kako je dolje navedeno, čime se dobije petero- ili šesteročlani prsten, ili ako Het predstavlja peteročlani prsten, CR2 može zajedno sa CR3 biti petero- ili šesteročlani alkilenski ili alkenililni prsten koji nije supstituiran ili je supstituiran;
R4 je fenil koji može biti supstituiran s jednim ili više sliejdećih radikala: halogen, nitro, cijano, hidroksil, merkapto, amino, C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, fenoksi, C1-C4-alkiltio, NH (C1-C4-alkil) ili N (C1-C4-alkil)2 ili fenil, koji može biti jednostruko ili višestruko, npr. jednostruko do trostruko supstituiran s halogenim nitro, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi ili sa C1-C4-alkiltio; ili
R5 je fenil ili 3, 4-dimetoksifenil;
R6 je C5-C7-cikloalkil, pri čemu ti radikali mogu biti u svakom slučaju jednostruko ili višestruko supstituirani sa C1-C4-alkoksi, C1-C4-alkilom, C1-C4-alkiltio, halogenim, hidroksilom, karboksilom, cijano, trifluormetilom, acetilom; ili fenil, koji može biti jednostruko ili višestruko, npr. jednostruko do trostruko supstituiran s halogenim, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi ili C1-C4-alkiltio;
fenil ili naftil, od kojih svaki može biti supstituiran s jednim ili više slijedećih radikala: halogen, nitro, merkapto, hidroksil, amino, C1-C4-alkil, C1-C4-haloalkil, acetil, C1-C4-alkoksikarbonil, C1-C4-alkoksi, C1-C4-haloalkoksi, fenoksi, C1-C4-alkiltio, NH (C1-C4-alkil), N (C1-C4-alkil)2, dioksometilen, dioksoetilen ili fenil koji može biti jednostruko ili višestruko, npr. trostruko supstituiran s halogenim, nitro, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi ili C1-C4-alkiltio;
petero- ili šesteročlani heteroaromatski sistem koji sadrži jedan do tri dušikova atoma i/ili jedan atom sumpora ili kisika, koji može nositi jedan do četiri halogena atoma i/ili jedan do dva slijedeća radikala: C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, trifluormetoksi, C1-C4-alkiltio, fenil ili fenoksi, pri čemu fenilni radikali sa svoje strane nose jedan do pet halogenih atoma i/ili jedan do tri slijedeća radikala: C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi i/ili C1-C4-alkiltio;
Z je sumpor ili kisik;
B je C3-alkilen;
Het je Ia gdje R2 i R3 predstavljaju metil i T je O, S.
Spojevi predloženog izuma nude novu terapeutsku mogućnost za liječenje hipertenzije, pulmonalne hipertenzije, infarkta miokarda, angine pectoris, akutnog/kroničnog otkazivanja bubrega, insuficijencije bubrega, cerebralnih vazospazmi, cerebralne ishemije, subarahnoidnih krvarenja, migrene, astme, ateroskleroze, endotoksičnog šoka, otkazivanja organa induciranih endotoksinom, intravaskularne koagulacije, restenoze nakon angioplastije, benigne hiperplazije prostate, ishemijskog i otkazivanja bubrega uzrokovanog intoksikacijom i hipertenzijom, metastaza i rasta mezenhimalnih tumora, otkazivanja bubrega induciranog kontrastnim sredstvom, pankreatitisa, gastrointestinalnog čira.
Izum se nadalje odnosi na kombinaciju proizvoda koja sadrži endotelin receptor antagoniste formule I i inhibitore sistema renin-angiotenzina. Inhibitori sistema renin-angiotenzina su renin inhibitori, angiotenzin II antagonisti i, posebno, inhibitori enzima koji pretvara angiotenzin (ACE, e. angiotensin converting enzyme).
Ta kombinacija proizvoda je posebno prikladna za liječenje i prevenciju hipertenzije i njenih posljedica, i za liječenje otkazivanja srca.
Dobro djelovanje spojeva može se pokazati u slijedećim pokusima:
Proučavanje vezanja receptora
Za proučavanje vezanja koriste se klonirane CHO-stanice koje eksprimiraju ETA- ili ETB-receptor.
Priprava membrana
CHO-stanice, koje eksprimiraju ETA- ili ETB-receptor, rastu su DMEM NUT MIX F12-mediju (Gibco, br. 21331-020) s 10% fetalnog telećeg seruma (PAA Laboratories GmbH, Linz, br. A15-022), 1 mM glutamina (Gibco br. 25030-024), 100 U/ml penicilina i 100 μg/ml streptomicina (Gibco, Sigma br. P-0781). Nakon 48 sati stanice se isperu s PBS-om i inkubiraju 5 minuta s PBS-om koji sadrži 0,05% tripsina. Nakon toga slijedi neutralizacija s medijem i stanice se skupe centrifugiranjem pri 300 x g.
Za pripravljanje membrana stanice se namjeste na koncentraciju od 108 stanica/ml pufera (50 ml Tris HCl pufer, pH 7,4) i zatim se dezintegriraju ultrazvukom (Branson Sonifier 250, 40-70 sekundi/konstantno/učin 20).
Ispitivanja vezanja
Za ispitivanje vezanja ETA- i ETB-receptora membrane se suspendiraju u inkubacijskom puferu (50 mM tris-HCl, ph 7,4 s 5 mM MnCl2, 40 μg/ml bacitracina i 0,2% BSA) u koncentraciji od 50 μg proteina po ispitnoj smjesi i inkubiraju se pri 25°C s 25 pM 125J-ET1 (ispitivanje ETA-receptora) ili 25 pM 125J-ET3 (ispitivanje ETB-receptora) u prisutnosti i odsutnosti ispitne tvari. Nespecifično vezanje određuje se s 10-7 M ET1. Nakon 30 minuta razdvoje se slobodan i vezani radioligand filtriranjem preko filtra od staklenih vlakana GF/B (Whatman, Engleska) na skupljaču stanica Skatron (Skatron, Lier, Norveška) i filtri se isperu s ledeno hladnim puferom tris-HCl, pH 7,4 s 0,2% BSA. Radioaktivnost skupljena na filtrima kvantitativno se odredi pomoću scintilacijskog brojača za tekućine Packard 2200 CA.
Ispitivanje ET-antagonista in vivo
Mužjaci SD štakora težine 250 - 300 g anestezirani su s amobarbitalom, priključeni na umjetno disanje, vagotomizirani i despinalizirani. Arteria carotis i vena su kateterizirane.
U skupini kontrolnih životinja intravensko davanje 1 μg/kg ET1 dovelo je do jasnog porasta krvnog tlaka, koji se je održao tijekom duljeg vremena.
Pokusnim životinjama, 30 minuta prije davanja ET1, ubrizgani su ispitni spojevi i.v. (1 mg/kg). Za određivanje ET-antagonističkih svojstava porast krvnog tlaka pokusnih životinja bio je uspoređen s onim kod kontrolnih životinja.
p.o. -ispitivanje miješanih ETA- i ETB-antagonista:
Mužjaci normotenzivnih štakora (Sprague Dawley, janvier) težine 250-350 g najprije su oralno primili ispitne tvari. 80 minuta kasnije životinje su anestetizirane e uretanom, a arteria carotis (za mjerenje krvnog tlaka) kao i vena jugularis (aplikacija big endotelin/endotelin 1) su kateterizirane.
Nakon faze stabilizacije, intravenski je dat big endotelin (20 μg/kg, aplicirani volumen 0,5 ml/kg), ili ET1 (0,3 μg/kg, aplicirani volumen 0,5 ml/kg). Krvni tlak i srčana frekvencija registrirani su kontinuirano tijekom 30 minuta. Jasne i trajne promjene krvnog tlaka računate su kao površine ispod krivulje (AUC). Za određivanje antagonističkog djelovanja ispitnih tvari AUC životinja koje su primile ispitne tvari uspoređen je s AUC-om kontrolnih životinja.
Spojevi prema izumu mogu se davati na uobičajen način oralno ili parenteralno (subkutano, intravenski, intramuskularno, intraperitonealno). Aplikacije se također mogu izvršiti s parama ili sprejevima putem nos-ždrijelo.
Doziranje ovisi o starosti, stanju i težini pacijenta, te o načinu aplikacije. U pravilu dnevna doza aktivne tvari iznosi između 0,5 i 50 mg/kg tjelesne težine kod oralnog davanja i između 0,1 i 10 mg/kg tjelesne težine kod parenteralnog davanja.
Novi spojevi mogu se primijeniti u uobičajenim krutim ili tekućim farmaceutskim oblicima, npr. kao neprevučene ili (s filmom) prevučene tablete, kapsule, prašak, granule, čepići, otopine, masti, kreme ili sprejevi. Oni se proizvesti na uobičajeni način. U tu svrhu aktivne tvari mogu se preraditi s uobičajenim farmaceutskim pomoćnim sredstvima kao što su veziva za tablete, punila, konzervansi, sredstva za rastvaranje tableta, sredstva za regulaciju tečenja, omekšivači, sredstvima za kvašanje, disperznati, emulgatori, otapala, sredstva za produženo oslobađanje aktivne tvari, antioksidanti i/ili potisni plinovi (usporedi H. Sucker et al.; Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1991). Tako dobiveni aplikacijski oblici sadrže aktivnu tvar obično količinom od 0,1 do 90 mas. %.
Primjeri sinteze
Primjer 1
Metil 2, 3-epoksi-3, 6-difenilheksanoat
1,4 g (31 mmol) 50%-tnog natrijevog hidrida doda se u obrocima tijekom 8 sati u otopinu od 4 g (17,8 mmolova) 1,4-difenil-1-butanona i 2,7 ml (31 mmol) metil klor acetata u 60 ml THF-a. Kad keton potpuno izreagira, reakcijsku smjesu se prenesu u led-vodu i ekstrahira s eterom. Organsku fazu se osuši preko magnezijevog sulfata, i kad otapalo potpuno izdestilira može se izolirati 5,5 g ulja u koje se koristi za slijedeću reakciju.
Primjer 2
Metil 2-hidroksi-metoksi-3,6-difenilheksanoat
2 g (6,75 mmola) metil 2,3-epoksi-3,6-difenilheksanoata unese se s 0,5 ml metanola u 20 ml diklormetana i doda se 5 kapi bor trifluorid eterata. Nakon 2 sata smjesu se zgusne i ostatak se očisti pomoću MPLC (gradijent cikloheksan/etil acetata) i izolira se 530 mg jednog diastereomera, 720 mg drugog diastereomera i 800 mg miješane frakcije.
Primjer 3
2-hidroksi-3-metoksi-3,6-difenilheksanska kiselina (jedan diastereomer, stereokemijski nepoznat)
Drugi diastereomer (720 mg, 2,2 mmola) otopi se u 9 ml dioksana i doda se 4,5 ml 1N otopine natrijevog hidroksida. Smjesu se miješa 16 sati i zatim se nakon dodatka vode ekstrahira s eterom. Vodenu fazu se zakiseli s limunskom kiselinom i ekstrahira s eterom, organsku fazu se osuši preko magnezijevog sulfata i otapalo se izdestilira. Izolirano je 936 mg ulja i ono je neposredno reagiralo dalje.
Primjer 4
2-(4-metoksi-6-metil-2-pirimidiniloksi)-3-metoksi-3,6-difenilheksanska kiselina (jedan diasteromer)
195 mg (4,4 mmola) 50%-tnog natrijevog hidrida, 465 mg (1,5 mmola) 2-hidroksi-3-metoksi-3,6-difenilheksanske kiseline i 291 mg (1,5 mmola) 3,4-dimetil-2-metilsulfonpirimidina pomiješa se u 20 ml DMF-a i miješa se 2 sata pri sobnoj temperaturi. Reakcijska smjesa se doda u 100 ml led-vode, zakiseli se s limunskom kiselinom i ekstrahira se s eterom. Organsku fazu se osuši s magnezijevim sulfatom i otapalo se izdestilira. Ostatak se očisti pomoću MPLC (gradijent cikloheksan/etil acetata) i izolira se 103 mg jednog diastereomera.
1H-NMR (200 MHz, CDCI3): 7,1-7,5 ppm (10 H, m); 6,2 (1H, s); 5,6 (1H, s); 3,8 (3H, s); 3,3 (3H, s); 2,5-2,8 (3H, m); 2,3 (3H, s); 2,0 (1H, m); 1,5-1,8 (2H, m).
ESI MS: M+ = 436
Primjer 5
Metil 2,3-epoksi-3-fenil-6-(3,4-metoksifenil) heksanoat (smjesa diastereomera)
12,6 g (44 mmola) 1-fenil-(3,4-dimetoksi) fenil-1-butanoata (sic) otopi se zajedno s 8,3 g metil kloracetata u 50 ml DMF-a i pri sobnoj temperaturi doda se u obrocima tijekom 1 sata u 3,7 g 50%-tne suspenzije natrijevog hidrida. Reakcija prekurzora je gotova za ukupno 1,5 sata i zatim se reakcijsku otopinu doda u 300 ml led-vode. Vodenu fazu se zakiseli s limunskom kiselinom i ekstrahira nekoliko puta s eterom. Organsku fazu se odvoji, ispere i osuši preko magnezijevog sulfata. Otapalo se izdestilira i izolira sse 13 g ulja koje može dalje odmah reagirati.
Primjer 6
Metil 2-hidroksi-3-(2-(3,4-dimetoksifenil)etoksi)-3-fenil-6-(3,4-dimetoksifenil) heksanoat
Smjesu od 3,6 g (10 mmolova) metil 2,3-epoksi-3-fenil-6-(3,4-metoksifenil) heksanoata, 1,8 g (10 mmolova) 2-(3,4-dimetoksi) etanola i 100 ml p-toluensulfonske kiseline u 50 ml diklormetana miješa se jedan sat uz hlađenje u ledu. Reakcijsku smjesu se doda u zasićenu otopinu natrijevog bikarbonata i organsku fazu se odvoji i osuši preko magnezijevog sulfata. Otapalo se izdestilira i 4,7 g ostatka se očisti pomoću MPLC (gradijent: cikloheksan/etil acetat) i izolira se 750 mg smjese diastereomera.
Primjer 7
2-hidroksi-3-(2-(3,4-dimetoksifenil) etoksi)-3-fenil-6-(3,4-dimetoksifenil) heksanska kiselina
2,1 ml 1N otopine natrijevog hidroksida doda se k 750 mg (1,4 mmola) metil 2-hidroksi-3-(2-(3,4-dimetoksifenil)-etoksi)-3-fenil-6-(3,4-dimetoksifenil) heksanoata otopljenog u 4,2 ml dioksana i smjesu se miješa 16 sati pri sobnoj temperaturi. U smjesu se doda 100 ml vode i to se zatim ekstrahira s eterom. Zatim se neutralizira sa solnom kiselinom, vodenu fazu se ekstrahira s eterom, fazu u eteru se osuši s magnezijevim sulfatom i otapalo se izdestilira. Izolira se 620 mg ulja i ono se upotrebljava neposredno dalje.
Primjer 8
2-(4,6-dimetil-2-pirimidiniloksi)-3-(2-(3,4-dimetoksifenil)etoksi)-3-fenil-6-(3,4-dimetoksifenil) heksanska
kiselina
164 mg (3,42 mmola) natrijevog hidrida , 600 mg (1,14 mmola) 2-hidroksi-3-(2-(3,4-dimetoksifenil)etoksi)-3-fenil-6-(3,4-dimetoksifenil) heksanske kiseline i 223 mg (1,2 mmola) 3,4-dimetil-2-metilsulfonpirimidina (sic) pomiješa se u 10 ml DMF-a i miješa se 6 sati pri sobnoj temperaturi. Reakcijsku smjesu se doda k 100 ml led-vode, zakiseli se s limunskom kiselinom i ekstrahira s eterom. Organsku fazu se osuši s magnezijevim sulfatom i otapalo se izdestilira. Ostatak se očisti vakuumskom kromatografijom (gradijent: cikloheksan/etil acetata) i izolira se 115 mg kristaliničnog diastereomera.
Diast. I:
talište: 93-96°C
ESI MS: M+ = 630
Primjer 9
2-(4,6-dimetil-2-pirimidiniloksi)-3-(3,4-dimetoksibenziloksi)-3-fenil-6-(3,4-dimetoksifenil) heksanska kiselina
Diast. I:
talište: 130-133°C
ESI MS: M+ = 616
Primjer 10
2-(4,6-dimetil-2-pirimidiniloksi)-3-(4-metoksifenoksi)-3-fenil-6-(3,4-dimetoksifenil) heksanska kiselina
Diast. I:
talište: 118-122°C
ESI MS: M+ = 572
Primjer 11
2-(4,6-dimetil-2-pirimidiniloksi)-3-metoksi-3-fenil-6-(3,4-dimetoksifenil) heksanska kiselina
Diast. I:
talište: 135-138°C
ESI MS: M+ = 480
Diast. II:
talište: 128-134ºC
ESI MS: M+ = 480
Primjer 12
2-(4,6-dimetil-2-pirimidiniloksi)-3-metoksi-3,6-difenilheksanska kiselina
1H-NMR (200 MHz, CDCI3): 7,1-7,5 ppm (10 H, m); 6,7 (1H, s); 5,8 (1H, s); 3,3 (3H, s); 2,5-2,7 (3H, m); 2,3 (6H, s); 2,0-2,1 (1H, m); 1,6-1,8 (2H, m).
ESI MS: M+ = 420
Primjer 13
2-(4,6-dimetil-2-pirimidiniloksi)-3-heks-3E-enoksi-3,6-difenilheksanska kiselina
Diast. I:
talište: 110-114°C
ESI MS: M+ = 488
Diast. II:
ESI MS: M+ = 488
Primjer 14
2-(4,6-dimetil-2-pirimidiniloksi)-3-(2-(3,4-dimetoksifenil) etoksi)-3,6-difenilheksanska kiselina
Diast. I:
talište: 87-88°C
ESI MS: M+ = 570
Diast. II:
talište: 87-88°C
ESI MS: M+ = 570
Primjer 15
2-(4-metoksi-6-metil-2-pirimidiniloksi)-3-(2-(3,4-dimetoksifenil) etoksi)-3,6-difenilheksanska kiselina
Diast. I:
talište: 141-142°C
ESI MS: M+ = 586
Primjer 16
2-(4,6-dimetil-2-pirimidiniloksi)-3-(3,4-dimetoksibenzil)-oksi)-3,6-difenilheksanska kiselina
Diast. I:
1H-NMR (200 MHz, CDCI3): 7,1-7,5 ppm (10 H, m); 6,9 (3H, m); 6,7 (1H, s); 5,8 (1H, s); 4,4 (1H, d); 4,3 (1H, d); 3,9 (3H, s); 3,85 (3H, s); 2,5-2,7 (3H, m); 2,3 (6H, s); 2,0-2,3 (1H, m); 1,7-1,9 (2H, m).
ESI MS: M+ = 556
Primjer 17
2-(4-metoksi-6-metil-2-pirimidiniloksi)-3-(3,4-dimetoksibenziloksi)-3,6-difenilheksanska kiselina
Diast. I:
1H-NMR (200 MHz, CDCI3): 7,1-7,5 ppm (10 H, m); 6,9 (3H, m); 6,25 (1H, s); 5,75 (1H, s); 4,45 (1H, d); 4,35 (1H, d); 3,9 (3H, s); 3,85 (6H, s); 2,4-2,7 (3H, m); 2,3 (6H, s); 2,0-2,2 (1H, m); 1,7-1,9 (2H, m).
ESI MS: M+ = 572
Primjer 18
2-(4-metoksi-6-metil-2-pirimidiniloksi)-3-(2-(2-tiofeniletoksi)-3,6-difenilheksanska kiselina
3:1 smjesa diastereomera:
raspadanje: 85°C
ESI MS: M+ = 532
Primjer 19
2-(4,6-dimetil-2-pirimidiniloksi)-3-(2-(3,4,5-trimetoksifenil) etoksi)-3,6-difenilheksanska kiselina
Diast. I:
1H-NMR (200 MHz, CDCl3): 7,0-7,3 ppm (10 H, m); 6,65 (1H, m); 6,4 (2H, s); 5,75 (1H, s); 3,9 (3H, s); 3,85 (6H, s); 3,5-3,7 (2H, m); 2,8-2,9 (2H, m); 2,3-2,5 (3H, m); 2,3 (6H, s); 2,0-2,3 (1H, m); 1,5-1,7 (2H, m).
ESI MS: M+ = 600
Primjer 20
2-(4-metoksi-6-metil-2-pirimidiniloksi)-3-(2-(3,4,5-trimetoksifenil) etoksi)-3,6-difenilheksanska kiselina
Diast. I:
talište: 153-155°C
ESI MS: M+ = 616
Primjer 21
2-(4,6-dimetil-2-pirimidiniloksi)-3-(2-(4-hidroksi-3-metoksifenil) etoksi)-3,6-difenilheksanska kiselina
Diast. I:
1H-NMR (200 MHz, CDCI3): 7,0-7,4 ppm (10 H, m); 6,9 (1H, m); 6,6-6,75 (3H, m); 5,8 (1H, s); 5,5 (OH); 3,9 (3H, s); 3,85 (3H, s); 3,5-3,7 (2H, m); 2,8-2,9 (2H, tr); 2,3-2,5 (3H, M); 2,3 (6H, s); 2,0-2,3 (1H, m); 1,5-1,7 (2H, m).
ESI MS: M+ = 556
Diast. II:
ESI MS: M+ = 556
Primjer 22
2-(4-metoksi-6-metil-2-pirimidiniloksi)-3-(2-(4-hidroksi-3-metoksifenil) etoksi)-3,6-difenilheksanska kiselina
Diast. I:
talište: 154-157°C
ESI MS: M+ = 572
Primjer 23
2-(4,6-dimetil-2-pirimidiniloksi)-3-(4-karboksibenziloksi)-3,6-difenilheksanska kiselina
Diast. I:
1H-NMR (200 MHz, CDCI3): 8,0 (2H, d); 7,1-7,5 ppm (12 H, m); 6,8 (1H, m); 6,8 (1H, s); 4,6 (1H, d); 4,5 (1H, d); 2,5-2,7 (3H, m); 2,3 (6H, s); 2,1-2,25 (1H, m); 1,5-1,7 (2H, m).
ESI MS: M+ = 540
Diast. II:
talište: 160-167°C
ESI MS: M+ = 540
Primjer 24
2-(4-metoksi-6-metil-2-pirimidiniloksi)-3-(4-karbokibenziloksi)-3,6-difenilheksanska kiselina
Diast. I:
1H-NMR (200 MHz, CDCI3): 8,0 (2H, d); 7,1-7,5 ppm (12 H, m); 6,2 (1H, m); 5,6 (1H, s); 4,55 (1H, d); 4,45 (1H, d); 3,9 (3H, s); 2,5-2,7 (3H, m); 2,3 (3H, s); 2,1-2,25 (1H, m); 1,6-1,8 (2H; m).
ESI MS: M+ = 556
Diast. II:
ESI MS: M+ = 556
Primjer 25
2-(4,6-dimetil-2-pirimidiniloksi)-3-(4-metoksifenil) oksi)-3,6-difenilheksanska kiselina
Diast. I:
1H-NMR (200 MHz, CDCl3): 7,1-7,5 ppm (10 H, m); 6,5-6,8 (5H, m); 5,9 (1H, s); 3,75 (3H, s); 2,2-2,7 (4H, m); 2,3 (6H, s); 1,5-1,7 (2H, m).
ESI MS: M+ = 512
Diast. II:
ESI MS: M+ = 512
Primjer 26
2-(4-metoksi-6-metil-2-pirimidiniloksi)-3-(4-metoksifenoksi)-3,6-difenilheksanska kiselina
Diast. I:
1H-NMR (200 MHz, CDCl3): 7,1-7,5 ppm (10 H, m); 6,5-6,9 (4H, m); 6,2 (1H, s); 5,75 (1H, s); 3,8 (3H, s); 3,75 (3H, s); 2,2-2,7 (4H, m); 2,3 (3H, s); 1,5-1,7 (2H, m).
ESI MS: M+ = 528
Diast. II:
ESI MS: M+ = 528
Primjer 27
2-(4,6-dimetil-2-pirimidiniloksi)-3-(3-(3,4,5-trimetoksifenil)-2E-propenoksi)-3,6-difenilheksanska kiselina
Diast. I:
1H-NMR (200 MHz, CDCl3): 7,1-7,4 ppm (10 H, m); 6,6 (1H, s); 6,55 (2H, s); 6,3 (1H, s); 6,2 (1H, dtr); 5,9 (1H, d); 4,0-4,2 (1H, m); 3,85 (3H, s); 3,8 (3H, s); 3,75 (3H, s); 3,4 (1H, m); 2,4-2,7 (3H, m); 2,3 (6H, s); 2,0-2,1 (1H, s); 1,5-1,7 (2H, m).
ESI MS: M+ = 612
Spojevi navedeni u tablici 1 mogu se proizvesti na sličan način ili kako je opisano u općem dijelu.
Tablica 1
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
2* = 2- (4,5-dimetiltiazolil) ;1* = 2- (4,5-dimetiloksazolil)
Primjer 12
U skladu s gore opisanim ispitivanjem vezanja izmjerene su vrijednosti vezanja receptora za dolje navedene spojeve.
Rezultati su prikazani u tablici 2.
Tablica 2
Vrijednosti vezanja receptora (Ki-vrijednosti)
[image]
Claims (2)
1. Derivati karboksilne kiseline formule I
[image]
naznačeni time, da supstituenti imaju slijedeća značenja:
R predstavlja tetrazol (sic) ili skupinu
[image]
R1 je radikal OR7 gdje
R7 predstavlja vodik, kation alkalijskog metala, aktion zemno alkalijskog metala ili fiziološki podnošljiv organski amonijev ion;
C3-C8-cikloalkil; C1-C8-alkil,
CH2-fenil, supstituiran ili nesupstituiran,
C3-C8-alkenilnu ili C3-C8-alkinilnu skupinu, nesupstituiranu ili supstituiranu, ili
fenil, supstituiran ili nesupstituiran,
R2 je vodik, hidroksil, NH2, NH (C1-C4-alkil), N (C1-C4-alkil)2, halogen, C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi ili C1-C4-alkiltio, ili je CR2 vezan na CR10, kako je dolje navedeno, čime se dobije petero- ili šesteročlani prsten, ili ako Het predstavlja peteročlani prsten, CR2 također može biti zajedno sa CR3 petero- ili šesteročlani alkenilni ili alkinilni prsten koji nije supstituiran ili je supstituiran;
X je dušik ili metin;
Y je dušik ili metin;
W je dušik ili CR10, gdje R10 predstavlja vodik ili C1-C4-alkil, ili CR10 zajedno sa CR2 ili CR3 oblikuje petero- ili šesteročlani alkilenski ili alkenilni prsten, koji nije supstituiran ili je supstituiran, i u kojem u svakom slučaju jedna ili više metilenskih skupina može biti nadomješteno s kisikom, sumporom, -NH ili NH (C1-C4-alkilom);
R3 je vodik, hidroksil, NH2, NH (C1-C4-alkil), N (C1-C4-alkil)2, halogen, C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, C1-C4-alkiltio; ili je CR3 povezan na CR10 kako je gore navedeno čime se dobije petero- ili šesteročlani prsten;
R4 i R3 (koji mogu biti jednaki ili različiti) jesu:
fenil ili naftil, nesupstituiran ili supstituiran, ili
fenil ili naftil koji su izravnom vezom zajedno povezani u orto položajima, metilenska, etilenska ili etenilenska skupina, kisikov ili sumporni atom ili SO2, NH ili N-alkilna skupina,
C3-C8-cikloalkil, nesupstituiran ili supstituiran;
R6 je vodik, C1-C8-alkil, C3-C8-alkenil ili C3-C8-alkinil, pri čemu svaki od tih radikala može biti jednostruko ili višestruko supstituiran s halogenim, hidroksilom, merkapto, karboksilom, nitro, amino, cijano, C1-C4-alkoksi, C3-C6-alkeniloksi, C3-C6-alkiniloksi, C1-C4-alkiltio , C1-C4-haloalkoksi, C1-C4-alkilkarbonil, C1-C4-alkoksikarbonilom, C3-C8-alkilkarbonilalkilom, NH (C1-C4-alkilom), N (C1-C4-alkilom)2, C3-C8-cikloalkilom, hetariloksi ili hetarilom, petero- ili šesteročlanim, koji sadrži jedan do tri dušikova atoma i/ili sumporni ili kisikov atom, fenoksi ili fenilom, pri čemu spomenuti arilni radikali sa svoje strane mogu biti jednostruko ili višestruko, npr. jednostruko do trostruko, supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi, amino, NH (C1-C4-alkilom), N (C1-C4-alkilom)2 ili C1-C4-alkiltio;
fenil ili naftil, od kojih svaki može biti jednostruko ili višestruko supstituiran sa slijedećim radikalima: halogen, nitro, cijano, hidroksil, amino, C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, fenoksi, C1-C4-alkiltio, C1-C4-alkilamino, C1-C4-dialkilamino, diokso-metilen ili dioksoetilen;
petero- ili šesteročlani heteroaromatski sistem koji sadrži jedan do tri dušikova atoma i/ili jedan atom sumpora ili kisika, koji može nositi jedan do četiri halogena atoma i/ili jedan do dva slijedeća radikala: C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, C1-C4-alkiltio, fenil, fenoksi ili fenilkarbonil, pri čemu fenilni radikali sa svoje strane nose jedan do pet halogenih atoma i/ili jedan do tri slijedeća radikala: C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi i/ili C1-C4-alkiltio;
C3-C8-cikloalkil, pri čemu ti radikali mogu biti jednostruko ili višestruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano, C1-C4-alkilom, C2-C4-alkenilom, C2-C4-alkinilom, C1-C4-alkoksi, C1-C4-alkiltio, C1-C4-haloalkoksi;
Z je sumpor ili kisik;
B je C2-C4-alkilen;
Het je heterociklički radikal formule Ia ili Ib
[image]
gdje
T je O, S ili NR8;
R8 je C1-C6-alkil,
njihove fiziološki podnošljive soli i enantiomerno čisti oblici.
2. Upotreba derivata karboksilnih kiselina prema zahtjevu 1, naznačena time, da se oni koriste za proizvodnju pred-lijekova.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19738578A DE19738578A1 (de) | 1997-09-04 | 1997-09-04 | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
DE1998111915 DE19811915A1 (de) | 1998-03-18 | 1998-03-18 | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP980484A2 true HRP980484A2 (en) | 1999-06-30 |
Family
ID=26039663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR19811915.1A HRP980484A2 (en) | 1997-09-04 | 1998-09-02 | Novel carboxylic acid derivatives, their production and their their use as mixed eta/etb receptor antagonists |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1009741A1 (hr) |
JP (1) | JP2001514254A (hr) |
KR (1) | KR20010023615A (hr) |
CN (1) | CN1269792A (hr) |
AR (1) | AR017052A1 (hr) |
AU (1) | AU748610B2 (hr) |
BG (1) | BG104222A (hr) |
BR (1) | BR9811631A (hr) |
CA (1) | CA2302350A1 (hr) |
CO (1) | CO4970738A1 (hr) |
HR (1) | HRP980484A2 (hr) |
HU (1) | HUP0004935A3 (hr) |
ID (1) | ID25620A (hr) |
IL (1) | IL134276A0 (hr) |
NO (1) | NO20001077L (hr) |
NZ (1) | NZ502660A (hr) |
PL (1) | PL338954A1 (hr) |
SK (1) | SK1522000A3 (hr) |
TR (1) | TR200000602T2 (hr) |
TW (1) | TW546295B (hr) |
WO (1) | WO1999011629A1 (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19924892A1 (de) * | 1999-06-01 | 2000-12-07 | Basf Ag | Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten |
US20090263472A1 (en) * | 2006-05-29 | 2009-10-22 | Nicox S.A. | Endothelin receptor antagonist derivatives |
PL2268644T3 (pl) | 2008-03-05 | 2012-01-31 | Boehringer Ingelheim Int | Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania |
JP5531097B2 (ja) * | 2009-07-10 | 2014-06-25 | カディラ・ヘルスケア・リミテッド | アンブリセンタンを調製するための改善された方法およびその新規な中間体 |
US20120053197A1 (en) | 2010-02-19 | 2012-03-01 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
US9150583B2 (en) | 2011-08-17 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4411225A1 (de) * | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
JP2000504013A (ja) * | 1996-02-01 | 2000-04-04 | スミスクライン・ビーチャム・コーポレイション | エンドセリンレセプターアンタゴニスト |
DE19614542A1 (de) * | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
DE19636046A1 (de) * | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
-
1998
- 1998-08-24 HU HU0004935A patent/HUP0004935A3/hu unknown
- 1998-08-24 SK SK152-2000A patent/SK1522000A3/sk unknown
- 1998-08-24 KR KR1020007002264A patent/KR20010023615A/ko not_active Application Discontinuation
- 1998-08-24 CN CN98808862A patent/CN1269792A/zh active Pending
- 1998-08-24 CA CA002302350A patent/CA2302350A1/en not_active Abandoned
- 1998-08-24 IL IL13427698A patent/IL134276A0/xx unknown
- 1998-08-24 BR BR9811631-2A patent/BR9811631A/pt not_active IP Right Cessation
- 1998-08-24 JP JP2000508669A patent/JP2001514254A/ja active Pending
- 1998-08-24 PL PL98338954A patent/PL338954A1/xx unknown
- 1998-08-24 AU AU95333/98A patent/AU748610B2/en not_active Ceased
- 1998-08-24 NZ NZ502660A patent/NZ502660A/en unknown
- 1998-08-24 WO PCT/EP1998/005354 patent/WO1999011629A1/de not_active Application Discontinuation
- 1998-08-24 EP EP98948859A patent/EP1009741A1/de not_active Withdrawn
- 1998-08-24 TR TR2000/00602T patent/TR200000602T2/xx unknown
- 1998-08-24 ID IDW20000386D patent/ID25620A/id unknown
- 1998-09-02 HR HR19811915.1A patent/HRP980484A2/hr not_active Application Discontinuation
- 1998-09-03 AR ARP980104402A patent/AR017052A1/es not_active Application Discontinuation
- 1998-09-03 TW TW087114595A patent/TW546295B/zh active
- 1998-09-03 CO CO98050561A patent/CO4970738A1/es unknown
-
2000
- 2000-03-02 NO NO20001077A patent/NO20001077L/no not_active Application Discontinuation
- 2000-03-06 BG BG104222A patent/BG104222A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU748610B2 (en) | 2002-06-06 |
CA2302350A1 (en) | 1999-03-11 |
AR017052A1 (es) | 2001-08-22 |
BR9811631A (pt) | 2000-09-26 |
CN1269792A (zh) | 2000-10-11 |
CO4970738A1 (es) | 2000-11-07 |
PL338954A1 (en) | 2000-12-04 |
JP2001514254A (ja) | 2001-09-11 |
HUP0004935A3 (en) | 2001-12-28 |
BG104222A (en) | 2001-02-28 |
WO1999011629A1 (de) | 1999-03-11 |
KR20010023615A (ko) | 2001-03-26 |
NO20001077D0 (no) | 2000-03-02 |
TW546295B (en) | 2003-08-11 |
SK1522000A3 (en) | 2000-08-14 |
EP1009741A1 (de) | 2000-06-21 |
IL134276A0 (en) | 2001-04-30 |
NO20001077L (no) | 2000-03-02 |
ID25620A (id) | 2000-10-19 |
TR200000602T2 (tr) | 2000-12-21 |
HUP0004935A2 (hu) | 2001-10-28 |
AU9533398A (en) | 1999-03-22 |
NZ502660A (en) | 2002-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK25999A3 (en) | Azinyloxy-and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed eta/etb endothelin receptor antagonists | |
HRP980560A2 (en) | New carboxylic acid derivatives, carrying amido side-chains, their production and use as endothelin receptor antagonists | |
HRP980484A2 (en) | Novel carboxylic acid derivatives, their production and their their use as mixed eta/etb receptor antagonists | |
HRP970686A2 (en) | Heterocyclic carboxylic acid derivatives, their preparation and use as endothelin receptor antagonists | |
HRP980331A2 (en) | New beta-amino and beta-azido carboxylic acid derivatives, the production and the use thereof as endothelin receptor antagonists | |
HRP20000602A2 (en) | 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists | |
HRP980591A2 (en) | Novel heterocyclically substituted alpha-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists | |
HRP20000650A2 (en) | Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed et<->a<p>/et<->b<p> receptor antafonists | |
HRP20010164A2 (en) | New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists | |
MXPA00001479A (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta | |
MXPA02000616A (es) | Derivados de acidos carboxilicos, novedosos, con anillo pirimidina sustituido en las posiciones 5, 6, su preparacion y uso como antagonistas de los receptores para endotelina. | |
CA2375666A1 (en) | Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists | |
HRP970503A2 (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb receptor antagonists | |
DE19738578A1 (de) | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten | |
MXPA00006463A (en) | 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists | |
DE19811915A1 (de) | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten | |
CZ20002963A3 (cs) | Nové deriváty karboxylové kyseliny, obsahující 5- substituovaný pyrimidinový kruh, jejich příprava a použiti | |
CZ61999A3 (cs) | Deriváty azinyloxy a fenoxy-diarylkarboxylových kyselin, způsob jejich přípravy a použití jako smíšených antagonistů ETA/ETB endotelinových receptorů | |
CZ2000743A3 (cs) | Deriváty kyseliny karboxylové a jejich použití |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODBI | Application refused |